- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT06619509
이 약에 대한 이전 연구에 참여한 고형 종양 환자를 대상으로 브리기마들린의 장기 치료를 테스트하기 위한 연구
고형 종양 환자를 대상으로 한 경구 브리기마들린의 제2상, 단일군, 공개 라벨, 장기 안전성 롤오버 시험
This study is open to adults with solid tumours who received at least 4 cycles of treatment with brigimadlin in a previous study. The goal of this study is to find out how well people with solid tumours tolerate long-term treatment with brigimadlin. Brigimadlin is a so-called MDM2 inhibitor that was being developed to treat cancer.
All participants take brigimadlin as tablets once every 3 weeks at the study site. At study visits, doctors check participants' health and take note of any unwanted effects. At some study visits, doctors also check the size of the tumour and whether it has spread to other parts of the body. Participants are in the study as long as they benefit from treatment and can tolerate it.
연구 개요
연구 유형
등록 (실제)
단계
- 2 단계
연락처 및 위치
연구 장소
-
-
-
Oslo, 노르웨이, N-0379
- Oslo Universitetssykehus HF, Radiumhospitalet
-
-
-
-
-
Taipei, 대만, 11217
- Taipei Veterans General Hospital
-
-
-
-
-
København Ø, 덴마크, 2100
- Copenhagen University Hospital, Rigshospitalet
-
-
-
-
-
Berlin, 독일, 13125
- Helios Klinikum Berlin-Buch
-
Tübingen, 독일, 72076
- Universitätsklinikum Tübingen
-
-
-
-
California
-
Beverly Hills, California, 미국, 90212
- Precision NextGen Oncology
-
Santa Monica, California, 미국, 90403
- Sarcoma Oncology Center
-
-
Connecticut
-
New Haven, Connecticut, 미국, 06511
- Yale Cancer Center
-
-
Florida
-
Jacksonville, Florida, 미국, 32224
- Mayo Clinic Cancer Center
-
-
Missouri
-
St Louis, Missouri, 미국, 63108
- Washington University School of Medicine
-
-
Nebraska
-
Omaha, Nebraska, 미국, 68130
- Nebraska Cancer Specialists-Omaha-69066
-
-
New York
-
Lake Success, New York, 미국, 11042
- Northwell Health
-
-
Tennessee
-
Germantown, Tennessee, 미국, 38138
- West Cancer Center & Research Institute
-
Nashville, Tennessee, 미국, 37232
- Henry-Joyce Cancer Clinic
-
-
Texas
-
Houston, Texas, 미국, 77030
- The University of Texas MD Anderson Cancer Center
-
-
Utah
-
Salt Lake City, Utah, 미국, 84106
- Utah Cancer Specialists Cancer Center
-
-
Washington
-
Seattle, Washington, 미국, 98109
- Fred Hutchinson Cancer Research Center
-
-
Wisconsin
-
Madison, Wisconsin, 미국, 53792
- University of Wisconsin
-
-
-
-
-
Brussels, 벨기에, 1200
- Cliniques Universitaires Saint-Luc
-
Leuven, 벨기에, 3000
- UZ Leuven
-
-
-
-
-
Stockholm, 스웨덴, SE-171 76
- Karolinska Comprehensive Cancer Center
-
-
-
-
-
Aragon, 스페인, 50009
- Hospital Universitario Miguel Servet
-
Madrid, 스페인, 28040
- Fundación Jiménez Díaz
-
Madrid, 스페인, 28041
- Hospital Universitario 12 de Octubre
-
Madrid, 스페인, 28050
- Hospital Universitario HM Sanchinarro
-
Santiago de Compostela, 스페인, 15706
- Hospital Clínico de Santiago
-
-
-
-
-
CABA, 아르헨티나, C1120AAB
- Sanatorio Finochietto
-
-
-
-
-
Cambridge, 영국, CB2 0QQ
- Addenbrooke's Hospital
-
London, 영국, SW3 6JJ
- The Royal Marsden Hospital, Chelsea
-
London, 영국, NW12PQ
- University College Hospital
-
-
-
-
-
Tel Aviv, 이스라엘, 6423906
- Sourasky Medical Center
-
-
-
-
-
Milan, 이탈리아, 20133
- Fondazione IRCCS Istituto Nazionale dei Tumori
-
Padova, 이탈리아, 35128
- Istituto Oncologico Veneto IRCCS
-
-
-
-
-
Fukuoka, Fukuoka, 일본, 812-8582
- Kyushu University Hospital
-
Fukuoka, Fukuoka, 일본, 811-1395
- National Hospital Organization Kyushu Cancer Center
-
Kanagawa, Yokohama, 일본, 241-8515
- Kanagawa Cancer Center
-
Miyagi, Sendai, 일본, 980-8574
- Tohoku University Hospital
-
Okayama, Okayama, 일본, 700-8558
- Okayama University Hospital
-
Osaka, Osaka, 일본, 541-8567
- Osaka International Cancer Institute
-
Tokyo, Chuo-ku, 일본, 104-0045
- National Cancer Center Hospital
-
-
-
-
-
Guangzhou, 중국, 510060
- Sun Yat-Sen University Cancer Center
-
-
-
-
-
Olomouc, 체코, 77900
- University Hospital Olomouc
-
-
-
-
Alberta
-
Calgary, Alberta, 캐나다, T2N 5G2
- Arthur J. E. Child Comprehensive Cancer Centre
-
-
Ontario
-
Toronto, Ontario, 캐나다, M5G 2M9
- Princess Margaret Cancer Centre
-
-
-
-
-
Warsaw, 폴란드, 02-781
- Oncology Center-Maria Sklodowska-Curie Institute
-
-
-
-
-
Lyon, 프랑스, 69373
- CTR Leon Berard
-
Rennes, 프랑스, 35042
- CTR Eugène Marquis
-
-
-
-
-
Gyöngyös, 헝가리, 3200
- Clinexpert Gyongyos
-
-
-
-
New South Wales
-
Randwick, New South Wales, 호주, 2031
- Prince of Wales Hospital-Randwick-66496
-
-
Queensland
-
Woolloongabba, Queensland, 호주, 4102
- Princess Alexandra Hospital
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion criteria:
- Patient is ongoing on brigimadlin treatment in any trial sponsored by Boehringer Ingelheim (hereafter referred to as the 'parent trial').
- Provision of signed and dated, written informed consent form (ICF) in accordance with International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use - Good Clinical Practice (ICH-GCP) and local legislation prior to any trial-specific procedures, sampling, or analyses.
- Women of childbearing potential (WOCBP) and men able to father a child must be ready and able to use 2 medically acceptable methods of birth control per ICH M3 (R2) that result in a low failure rate of <1% per year when used consistently and correctly beginning at Screening, during trial participation, and until 6 months and 12 days after the last dose for women and 102 days after the last dose for men. A list of contraception methods meeting these criteria and instructions on the duration of use is provided in the participant information.
- Participants must be willing and able to comply with the scheduled visits, treatment plan, lifestyle, laboratory tests, contraceptive guidelines, and other study procedures.
- Adequate organ function.
- Patient is eligible to receive continued treatment according to the clinical trial protocol of the parent trial they are currently participating in. Patients currently experiencing a dose delay in the parent trial due to adverse events are eligible if recovery from the adverse event takes place within the allowed time window in the parent trial.
Exclusion criteria:
- Any medical condition which in the opinion of the investigator should exclude the patient from receiving treatment with brigimadlin.
- Participants who must receive or intend to receive restricted medications or any drug considered likely to interfere with the safe conduct of the trial.
- Women who are pregnant, nursing, or who plan to become pregnant while in the trial. Female patients who do not agree to the interruption of breastfeeding from the start of study treatment until 6 months and 12 days after the last dose of study treatment.
- Patient has unacceptable toxicity on brigimadlin at the time of transition into this trial.
- Patient has an adverse event (AE) which has caused a dose delay and has not recovered within the allowed time window in the parent trial.
- Patient who has already required 2 dose reductions and would require a third dose reduction at trial entry, unless the investigator deems treatment continuation beneficial, and the third dose reduction is agreed in writing between the investigator and the sponsor.
Further exclusion criteria apply.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 해당 없음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: 브리기마들린
|
Brigimadlin
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
The primary endpoint will be the occurrence of treatment-emergent adverse events (AEs) according to CTCAE Version 5.0 during the entire treatment period
기간: up to 9 years.
|
CTCAE=Common Terminology Criteria for Adverse Events |
up to 9 years.
|
공동 작업자 및 조사자
간행물 및 유용한 링크
유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- 1403-0032
- 2024-514177-21-00 (레지스트리 식별자: CTIS)
- U1111-1305-3484 (레지스트리 식별자: WHO International Clinical Trials Registry Platform (ICTRP))
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
Once the criteria in section 'time frame' are fulfilled, researchers can use the following link https:// www.mystudywindow.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed "Document Sharing Agreement". Furthermore, researchers can request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website.
IPD 공유 기간
One year after the approval has been granted by major Regulatory Authorities and after the primary manuscript has been accepted for publication, or after termination of the development program.
IPD 공유 액세스 기준
For study documents -upon signing of a 'Document Sharing Agreement'. For study data -1. after the submission and approval of the research proposal (checks will be performed by the sponsor and/or the independent review panel, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a legal agreement.
IPD 공유 지원 정보 유형
- 연구_프로토콜
- 수액
- CSR
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .